NCT03516123View on ClinicalTrials.gov

A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 14, 2018

Primary Completion Date

June 18, 2020

Study Completion Date

June 18, 2020

Conditions
Solid Tumor, Adult
Interventions
DRUG

CS3006

"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."

Trial Locations (1)

2010

St Vincent's hospital, Sydney

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY

NCT03516123 - A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter